Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Reform: US House Bills Mark The End Of The Beginning

Executive Summary

Energy & Commerce Health Subcommittee releases several discussion drafts at hearing on 340B drug discount program reform as the debate seems poised to move into the next phase.

You may also be interested in...



US 340B Discount Restrictions By Pharma: HRSA Will Continue To ‘Walk The Walk’ In Opposition

Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.

Pharma Manufacturers Mobilize Against 340B Discounts At Contract Pharmacies

AstraZeneca, Merck & Co., Sanofi and Novartis join Eli Lilly in taking action. But providers in the US federal discount program are pushing back.

Lilly Bars Contract Pharmacies From 340B Discounts Despite HRSA Guidance

Distribution limits for Cialis prompts concerns among 340B-eligible providers that Lilly will impose similar restrictions for additional products and that other manufacturers may follow suit.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS123478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel